TD Cowen reiterates Hold on Leidos stock amid contract concerns

TD Cowen reiterated a Hold on Leidos with a $135 price target, citing risk to the VA medical disability exam contract, which it estimates will account for $2 billion of 2026 sales and roughly 30% of 2026 EPS. The firm cut its 2027 EPS estimate to $11.74 from a Street consensus of $12.78 and forecasts Health segment margins of 17.5% versus the Street’s 19.8%, as less favorable contract pricing takes effect. Leidos nonetheless beat Q2 2026 expectations with adjusted EPS of $3.26 versus $2.91 expected and revenue of $4.56 billion versus $4.44 billion, and raised full-year guidance.

Analysis

The key issue is not the next quarter but a multi-year earnings-quality discount: a concentrated, high-contribution program moving to a bundled rebid makes the downside discontinuous rather than a normal pricing headwind. The current 2027 estimate gap is roughly 8% versus consensus, but a loss of even part of the work would create a materially larger earnings reset and likely pressure LDOS's defense-contractor valuation multiple. Near-term cash conversion and defense backlog can cushion the stock, so the market may not fully price the risk until procurement milestones become visible.

MMS is the most credible relative beneficiary because it has incumbent capability across the relevant service categories and healthcare-administration infrastructure. However, bundled procurement raises bid-complexity and execution requirements; this is not a clean zero-sum share-transfer trade, since aggressive pricing by either incumbent can damage both companies' margins even if they retain volume. The more likely first-order outcome is margin dilution before any award decision, with customer purchasing power strengthening as the rebid approaches.

Consensus appears vulnerable over the next 1-3 months if Health profitability remains below prior expectations and management does not offset it with other segments. The decisive 6-18 month catalyst is RFP structure, bidder participation, and award timing; an above-consensus Health margin trajectory or explicit evidence that incumbency is being protected would falsify the bearish LDOS view. The stock's large drawdown alone is not a catalyst for mean reversion when the earnings-base durability question remains unresolved.

Key Decisions for Investors

• Maintain an underweight/short bias in LDOS into the next Health-margin disclosure; target an additional 8-12% downside if 2027 consensus begins converging toward the lower estimate range. Cover if management demonstrates sustained Health margin above 20% or raises 2027 earnings expectations despite the rebid exposure.
• Use a relative-value expression: long MMS versus short LDOS over a 3-6 month horizon, sized modestly because both firms face pricing risk. The trade works if procurement uncertainty shifts valuation premium toward the less defense-multiple-dependent healthcare administrator; exit if MMS signals comparable margin concessions or loses meaningful incumbent scope.
• Do not buy LDOS solely on valuation weakness before the procurement timetable is clarified. Set alerts for RFP release, contract-award rules, disclosed bidder count, and any customer decision to preserve regional separability; these variables determine whether the risk is a margin haircut or a binary revenue loss.
• For existing LDOS longs, consider 6-12 month downside hedges rather than selling broad defense exposure: the company-specific Health reset is more actionable than a sector short, while defense demand can offset part of the earnings drag.